187 related articles for article (PubMed ID: 23962310)
1. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.
Labruijere S; Ibrahimi K; Chan KY; Maassenvandenbrink A
Expert Opin Drug Discov; 2013 Nov; 8(11):1309-23. PubMed ID: 23962310
[TBL] [Abstract][Full Text] [Related]
2. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
Edvinsson L
Br J Clin Pharmacol; 2015 Aug; 80(2):193-9. PubMed ID: 25731075
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
Bell IM
J Med Chem; 2014 Oct; 57(19):7838-58. PubMed ID: 24960305
[TBL] [Abstract][Full Text] [Related]
4. Side effects associated with current and prospective antimigraine pharmacotherapies.
González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
[TBL] [Abstract][Full Text] [Related]
5. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
Gupta S; Villalón CM
Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
[TBL] [Abstract][Full Text] [Related]
6. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine.
Rudolf K; Eberlein W; Engel W; Pieper H; Entzeroth M; Hallermayer G; Doods H
J Med Chem; 2005 Sep; 48(19):5921-31. PubMed ID: 16161996
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatment for chronic migraine and refractory chronic migraine.
Lionetto L; Negro A; Palmisani S; Gentile G; Del Fiore MR; Mercieri M; Simmaco M; Smith T; Al-Kaisy A; Arcioni R; Martelletti P
Expert Opin Emerg Drugs; 2012 Sep; 17(3):393-406. PubMed ID: 22862686
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
Bigal ME; Walter S; Rapoport AM
Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
[TBL] [Abstract][Full Text] [Related]
9. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects.
Chan KY; Vermeersch S; de Hoon J; Villalón CM; Maassenvandenbrink A
Pharmacol Ther; 2011 Mar; 129(3):332-51. PubMed ID: 21130807
[TBL] [Abstract][Full Text] [Related]
10. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
[TBL] [Abstract][Full Text] [Related]
11. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
Villalón CM; Olesen J
Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
[TBL] [Abstract][Full Text] [Related]
12. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.
Hougaard A; Tfelt-Hansen P
Expert Opin Drug Metab Toxicol; 2015; 11(9):1409-18. PubMed ID: 26095133
[TBL] [Abstract][Full Text] [Related]
13. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.
Tajti J; Csáti A; Vécsei L
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1509-20. PubMed ID: 25253587
[TBL] [Abstract][Full Text] [Related]
14. CGRP receptor antagonists: toward a novel migraine therapy.
Salvatore CA; Kane SA
Curr Pharm Biotechnol; 2011 Oct; 12(10):1671-80. PubMed ID: 21466447
[TBL] [Abstract][Full Text] [Related]
15. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.
Hostetler ED; Joshi AD; Sanabria-Bohórquez S; Fan H; Zeng Z; Purcell M; Gantert L; Riffel K; Williams M; O'Malley S; Miller P; Selnick HG; Gallicchio SN; Bell IM; Salvatore CA; Kane SA; Li CC; Hargreaves RJ; de Groot T; Bormans G; Van Hecken A; Derdelinckx I; de Hoon J; Reynders T; Declercq R; De Lepeleire I; Kennedy WP; Blanchard R; Marcantonio EE; Sur C; Cook JJ; Van Laere K; Evelhoch JL
J Pharmacol Exp Ther; 2013 Nov; 347(2):478-86. PubMed ID: 23975906
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
17. CGRP inhibitors for migraine prophylaxis: a safety review.
Rivera-Mancilla E; Villalón CM; MaassenVanDenBrink A
Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190
[TBL] [Abstract][Full Text] [Related]
18. Targeting CGRP: A New Era for Migraine Treatment.
Wrobel Goldberg S; Silberstein SD
CNS Drugs; 2015 Jun; 29(6):443-52. PubMed ID: 26138383
[TBL] [Abstract][Full Text] [Related]
19. CGRP antagonists and antibodies for the treatment of migraine.
Vécsei L; Szok D; Csáti A; Tajti J
Expert Opin Investig Drugs; 2015 Jan; 24(1):31-41. PubMed ID: 25219387
[TBL] [Abstract][Full Text] [Related]
20. Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.
Lynch JJ; Shen YT; Pittman TJ; Anderson KD; Koblan KS; Gould RJ; Regan CP; Kane SA
Eur J Pharmacol; 2009 Nov; 623(1-3):96-102. PubMed ID: 19766109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
